US Patent 9,296,769: Tenofovir Alafenamide Hemifumarate Claims, Scope, Expiration and Patent Landscape
US Patent 9,296,769 protects pharmaceutical compositions containing tenofovir alafenamide hemifumarate, or TAF hemifumarate, with controlled levels of the mono-fumarate impurity. Its strongest protection is directed to the chemical form and purity profile of TAF hemifumarate, not to a particular branded tablet. The patent also contains formulation, combination-therapy, HIV-treatment, HBV-treatment, dosing, and manufacturing claims.
The patent is assigned to Gilead Sciences, Inc. and was issued on March 29, 2016. Its nominal US patent-term expiration is March 15, 2033, subject to any applicable patent-term adjustment or extension reflected in official USPTO and FDA records. The patent is relevant to TAF products including Vemlidy, Descovy, Genvoya, Odefsey, and Biktarvy because those products use TAF hemifumarate or formulations derived from that active pharmaceutical ingredient.
What does US Patent 9,296,769 protect?
The patent protects a composition containing TAF hemifumarate with less than approximately 5% TAF monofumarate. The independent composition claim is claim 1:
"A composition comprising tenofovir alafenamide hemifumarate, wherein the composition comprises less than about 5% by weight of tenofovir alafenamide monofumarate."
The claim does not require a tablet, capsule, specific excipient, dose, therapeutic indication, or particular commercial product. It can therefore reach the active ingredient before it is incorporated into a finished dosage form.
The principal protected features are:
| Feature |
Claim coverage |
| Active pharmaceutical ingredient |
TAF hemifumarate |
| Impurity limitation |
Less than about 5 wt% TAF monofumarate |
| Narrower impurity limits |
Less than about 1 wt% and less than about 0.5 wt% |
| Fumaric-acid ratio |
0.5 ± 0.1 and 0.5 ± 0.01 |
| Solid-state characterization |
XRPD peaks at 6.9 ± 0.2° and 8.6 ± 0.2° 2θ |
| Finished pharmaceutical composition |
TAF hemifumarate composition plus excipient |
| Combination products |
Addition of specified HIV drug classes |
| HIV treatment |
Administration for HIV infection |
| HBV treatment |
Administration for HBV infection |
| Manufacturing |
Combining the protected composition with an excipient |
| Dosing |
Multiple daily doses or single daily dose |
How strong are claims 1 through 6 for TAF hemifumarate?
Claims 1 through 6 form the core active-ingredient and solid-form estate.
Claim 1: less than 5% TAF monofumarate
Claim 1 is broad in chemical and formulation terms. It covers any composition containing TAF hemifumarate below the stated monofumarate threshold. The word "comprising" permits additional ingredients, impurities, polymorphs, excipients, and therapeutic agents unless their presence is inconsistent with the claim.
The main infringement questions would be:
- Whether the accused material contains TAF hemifumarate.
- Whether the amount of TAF monofumarate is below approximately 5% by weight.
- How "by weight" is calculated, including whether the denominator is the total composition, the active-ingredient fraction, or a specified analytical basis.
- Whether the measured result falls within the tolerance implied by "about."
The threshold is potentially enforceable against an API manufacturer, finished-dose manufacturer, or generic applicant whose product uses the claimed salt.
Claims 2 and 3: narrower purity thresholds
Claims 2 and 3 require less than approximately 1% and less than approximately 0.5% TAF monofumarate, respectively.
These claims have a narrower literal scope but may provide stronger practical protection because commercial pharmaceutical APIs are generally manufactured to controlled purity specifications. A product below 0.5% monofumarate would satisfy claims 1, 2, and 3, assuming the other claim limitations are met.
The claims create a nested structure:
- Below 0.5%: potentially within claims 1, 2, and 3.
- Between 0.5% and 1%: potentially within claims 1 and 2.
- Between 1% and 5%: potentially within claim 1 only.
- At or above approximately 5%: potentially outside the principal purity claims.
The use of "about" creates a claim-construction issue at the boundaries. Analytical method validation, batch variability, sampling, and laboratory error would be important in litigation.
Claims 4 and 5: fumaric-acid-to-TAF ratio
Claim 4 requires a fumaric-acid-to-TAF ratio of 0.5 ± 0.1, equivalent to a range of approximately 0.4 to 0.6.
Claim 5 narrows that ratio to 0.5 ± 0.01, equivalent to approximately 0.49 to 0.51.
These claims target the stoichiometric identity of the hemifumarate salt. The ratio limitation can distinguish TAF hemifumarate from TAF monofumarate:
- TAF hemifumarate corresponds approximately to 0.5 molar equivalent of fumaric acid per mole of TAF.
- TAF monofumarate corresponds approximately to 1.0 molar equivalent of fumaric acid per mole of TAF.
Claim 5 is technically narrower and may be easier to design around by producing a composition outside the 0.49-to-0.51 ratio, although a material that is deliberately outside the ratio may no longer be the same commercially useful hemifumarate form.
Claim 6: XRPD limitation
Claim 6 requires an X-ray powder diffraction pattern containing peaks at 6.9 ± 0.2° and 8.6 ± 0.2° 2θ.
This is a solid-state claim. It can provide evidence that the accused material has the claimed crystalline form, but peak presence alone may not resolve every infringement question. Relevant issues include:
- Instrument calibration.
- Radiation source and measurement conditions.
- Whether the peaks are characteristic or merely coincidental.
- Relative peak intensities.
- Sample preparation.
- Hydration, solvation, polymorphism, and crystallinity.
- Whether the claim requires only the listed peaks or a fuller pattern disclosed in the specification.
Because claim 6 depends on claim 1, both the TAF hemifumarate composition and the monofumarate impurity limitation remain relevant.
What do claims 7 through 9 protect?
Claims 7 through 9 extend the core composition into pharmaceutical products and combination therapies.
Claim 7: pharmaceutical composition with excipient
Claim 7 covers the composition of claim 1 combined with a pharmaceutically acceptable excipient. It can reach tablets, capsules, powders, granules, suspensions, and other dosage forms if they contain the claimed TAF hemifumarate composition.
The claim is not limited to a particular excipient, release profile, strength, or route of administration. A generic product containing TAF hemifumarate with conventional excipients could therefore raise a claim 7 issue even if it does not reproduce a branded formulation in every detail.
Claim 8: additional therapeutic agent
Claim 8 requires the pharmaceutical composition of claim 7 plus an additional therapeutic agent. Claim 9 identifies broad HIV drug classes, including:
- HIV protease inhibitors.
- Non-nucleoside reverse-transcriptase inhibitors.
- Nucleoside reverse-transcriptase inhibitors.
- Nucleotide reverse-transcriptase inhibitors.
- Integrase inhibitors.
- CCR5 inhibitors.
This language can encompass fixed-dose combinations and co-packaged or co-administered products, depending on claim construction and the physical requirements of "composition."
The claims are relevant to TAF combinations such as:
| Product |
TAF combination |
Relevance |
| Descovy |
TAF plus emtricitabine |
Falls within the listed NRTI combination category |
| Genvoya |
TAF, emtricitabine, elvitegravir, cobicistat |
Includes NRTI and integrase-inhibitor components |
| Odefsey |
TAF, emtricitabine, rilpivirine |
Includes NRTI and NNRTI components |
| Biktarvy |
TAF, emtricitabine, bictegravir |
Includes NRTI and integrase-inhibitor components |
| Vemlidy |
TAF alone |
Primarily relevant to composition and HBV method claims |
The claim language does not identify specific marketed products by name. Product mapping requires confirmation of the actual API form, impurity profile, dosage composition, and regulatory labeling.
What do claims 10 through 14 protect?
Claims 10 through 14 are method-of-treatment claims for HIV and HBV.
HIV treatment claims
Claims 10 and 11 cover administering the claim 1 composition or claim 7 pharmaceutical composition to treat HIV infection.
Claim 12 adds one or more therapeutic agents from the HIV drug classes listed in claim 9. This claim is particularly relevant to combination antiretroviral products.
HBV treatment claims
Claims 13 and 14 cover administering the TAF hemifumarate composition or pharmaceutical composition to treat HBV infection.
These claims are closely aligned with Vemlidy's approved indication for chronic hepatitis B in specified patient populations. The claims may also be relevant to off-label or investigational use, but actual infringement analysis depends on the accused party's conduct, labeling, inducement evidence, and the scope of the approved indication.
The treatment claims are narrower than a pure composition claim in one respect: they require the claimed administration for the specified infection. They may be difficult to assert against an API supplier absent evidence of intent or contribution to the claimed treatment.
What do claims 15 through 19 protect?
Claim 15: preparation of a pharmaceutical composition
Claim 15 covers combining the claim 1 composition with a pharmaceutically acceptable excipient. The claim is directed to a manufacturing step rather than merely the resulting product.
Potentially relevant activities include:
- Blending TAF hemifumarate with excipients.
- Granulation.
- Compression into tablets.
- Encapsulation.
- Preparation of an oral solid dosage form.
- Manufacture of a finished pharmaceutical product.
The claim does not specify a process temperature, solvent, equipment, mixing time, particle size, or tableting method. Its scope is therefore broad as a combination step, but it depends on the presence of the claim 1 composition.
Claims 16 through 19: dosing frequency
Claims 16 and 17 specify multiple daily dosing and single daily dosing for HIV treatment. Claims 18 and 19 apply the same alternatives to HBV treatment.
These claims have limited incremental commercial value where the marketed product is administered once daily, but they can protect specific labeled or clinical uses. The single-daily-dose claims are more directly relevant to standard TAF products such as Vemlidy and the major TAF-containing HIV combination products.
When does US Patent 9,296,769 expire?
The patent was issued on March 29, 2016. Public patent records identify March 15, 2033 as the nominal expiration date based on the underlying US/PCT filing chronology. The effective date used for Orange Book or litigation analysis should be checked against the current USPTO patent-term record, including any patent-term adjustment, terminal disclaimer, or patent-term extension.
| Event |
Date |
| Earliest reported priority |
March 16, 2012 |
| US/PCT filing chronology |
March 15, 2013 |
| US patent grant |
March 29, 2016 |
| Nominal patent expiration |
March 15, 2033 |
The 2033 date is later than the practical expiration of some earlier TAF compound or formulation rights. That makes US 9,296,769 potentially important as a late-expiring salt, purity, and solid-form patent.
What is the Orange Book status of US 9,296,769?
US 9,296,769 is associated with Gilead's TAF-containing products and has been treated as part of the patent estate relevant to FDA-approved TAF products. Orange Book relevance must be assessed product by product because FDA patent listings are submitted against specific approved applications rather than against an active ingredient in the abstract.
The principal products requiring review are:
- Vemlidy, NDA 208464.
- Descovy, NDA 208215.
- Genvoya, NDA 207561.
- Odefsey, NDA 208351.
- Biktarvy, NDA 210251.
An Orange Book listing can trigger a four-year or thirty-month framework under the Hatch-Waxman Act when an ANDA applicant submits a Paragraph IV certification and the NDA holder brings timely litigation. A patent that is not listed for a particular NDA may still be asserted in district court, but it does not create the same automatic FDA approval mechanics.
Which companies are challenging TAF patent rights?
The principal competitive challenge comes from generic pharmaceutical companies filing or preparing ANDAs for TAF-containing products. Publicly reported challenges have involved combinations and products associated with Gilead's HIV and HBV portfolio, including generic versions of Descovy, Vemlidy, Genvoya, Odefsey, and Biktarvy.
A Paragraph IV challenge to a listed patent may argue that:
- The patent is invalid for anticipation or obviousness.
- The claims are not infringed.
- The accused product does not contain the claimed hemifumarate form.
- The monofumarate impurity exceeds the claimed threshold.
- The XRPD peaks do not establish the claimed crystalline material.
- The method claims are not induced by the proposed label.
- The patent is unenforceable because of inequitable conduct or another litigation-specific defense.
The existence of an ANDA challenge does not establish that a generic product will launch. Launch timing depends on litigation outcomes, settlements, 180-day exclusivity, regulatory approval, pediatric or other exclusivity, and commercial risk.
What patent litigation and settlements affect TAF products?
The TAF patent landscape includes product-specific litigation involving Gilead and generic manufacturers. The relevant disputes generally fall into four groups:
- Compound and prodrug patents covering tenofovir alafenamide.
- Salt, purity, polymorph, and solid-form patents, including US 9,296,769.
- Formulation and fixed-dose-combination patents.
- Method-of-use patents for HIV and HBV treatment.
Settlement agreements in pharmaceutical patent disputes may provide an authorized-generic date, a license date, or a delayed launch date without resolving the underlying validity question. A settlement must therefore be analyzed separately from patent strength.
For diligence, the most important records are the FDA Orange Book, FDA Approved Drug Products with Therapeutic Equivalence Evaluations, USPTO Patent Center, district-court dockets, Federal Circuit opinions, and any filed settlement disclosures under the Medicare Modernization Act.
How does US 9,296,769 compare with competing TAF patent rights?
| Patent category |
Primary subject |
Commercial significance |
| TAF compound patents |
Chemical identity and prodrug structure |
Can block manufacture of TAF itself |
| US 9,296,769 |
Hemifumarate, monofumarate control, ratio, XRPD |
Targets the API form used in commercial products |
| Formulation patents |
Tablet composition, excipients, dissolution, dosage form |
Can delay product-specific generic entry |
| Combination patents |
TAF with emtricitabine, integrase inhibitors, NNRTIs, or boosters |
Relevant to Descovy, Genvoya, Odefsey, and Biktarvy |
| Method patents |
HIV or HBV treatment and dosing |
Relevant to labeling and induced-infringement theories |
| Manufacturing patents |
Salt formation, crystallization, purification, or processing |
Can create supply-chain barriers even if a formulation is designed around |
US 9,296,769 is strongest when the generic intends to use the same TAF hemifumarate material, a comparable purity specification, and the same or similar crystalline form. Its practical strength decreases if a competitor can lawfully use a different salt, amorphous form, polymorph, impurity profile, or manufacturing route without losing bioequivalence or regulatory acceptability.
What generic-entry risks exist for Vemlidy and TAF combination products?
Generic entry is unlikely to depend on this patent alone. The relevant question is whether a proposed generic can clear the complete patent and exclusivity stack.
Vemlidy
Vemlidy faces composition, solid-form, formulation, and method-of-use barriers. US 9,296,769 is most relevant to the API form and the HBV-use claims. A generic developer would likely need to address the patent through a Paragraph IV certification if it is listed against the relevant NDA.
Descovy and Odefsey
These products add combination and formulation risks. Even if a generic avoids a particular TAF hemifumarate claim, separate patents may cover the fixed-dose combination, dosage form, or labeled use.
Genvoya
Genvoya has multiple active ingredients and a more complex formulation. Generic development must address the TAF component, the combination, the pharmacokinetic role of cobicistat, and product-specific formulation patents.
Biktarvy
Biktarvy has a newer commercial position and combination-specific patent exposure. The presence of TAF does not make US 9,296,769 the only relevant patent. Bictegravir combination and formulation rights may be more commercially decisive for Biktarvy entry.
How strong is the patent estate for US 9,296,769?
The estate has four principal strengths:
- It claims the active salt rather than only a finished dosage form.
- It uses purity and stoichiometric limitations that align with pharmaceutical manufacturing specifications.
- It includes an XRPD limitation that can support solid-form identification.
- It covers both HIV and HBV methods, including once-daily administration.
Its principal vulnerabilities are claim-specific:
- The hemifumarate form may have been challenged through prior-art salt disclosures.
- The impurity thresholds may be vulnerable to enablement, written-description, or obviousness arguments if the prior art taught comparable purification.
- The fumaric-acid ratio may be avoided by a different salt or solid form.
- XRPD claims can create factual disputes over analytical methodology and sample identity.
- Treatment claims may depend on the exact label and commercial instructions.
- Dependent claims do not protect a product unless all parent-claim limitations are satisfied.
What manufacturing and geographic barriers does the patent create?
The patent is a US right. It does not independently block manufacture, sale, or use outside the United States. Separate national patent rights must be assessed in Europe, Canada, Japan, China, India, and other markets.
For US supply chains, the material most exposed is TAF hemifumarate API manufactured to low monofumarate levels. A supplier that produces the same hemifumarate with a ratio near 0.5 and the claimed XRPD pattern faces a higher infringement risk than a supplier using a distinct salt or solid form.
A design-around strategy could involve:
- A different TAF salt.
- An amorphous TAF form.
- A polymorph lacking the claimed XRPD peaks.
- A composition with a monofumarate level outside the claimed threshold.
- A manufacturing process that produces a non-infringing material.
Regulatory feasibility remains the limiting factor. A chemically distinct form must still satisfy pharmaceutical quality, stability, bioequivalence, safety, and FDA approval requirements.
Key Takeaways
- US 9,296,769 is a Gilead patent directed to TAF hemifumarate compositions.
- Claim 1 covers TAF hemifumarate containing less than approximately 5% TAF monofumarate.
- Claims 2 and 3 narrow the impurity threshold to approximately 1% and 0.5%.
- Claims 4 and 5 protect a fumaric-acid-to-TAF ratio centered on 0.5.
- Claim 6 protects a specified XRPD signature associated with the solid form.
- Claims 7 through 9 extend protection to pharmaceutical and combination products.
- Claims 10 through 14 cover HIV and HBV treatment methods.
- Claims 15 through 19 cover preparation and dosing methods.
- The nominal expiration date is March 15, 2033, subject to the official patent-term record.
- Generic entry for Vemlidy and TAF combination products will depend on the complete Orange Book, exclusivity, litigation, settlement, formulation, and combination-patent landscape.
- The patent is strongest against products using the same TAF hemifumarate API, comparable purity, and the claimed crystalline form.
FAQs
Does US 9,296,769 cover tenofovir alafenamide itself?
No. The claims are directed to a composition containing TAF hemifumarate with defined monofumarate, stoichiometric, or XRPD characteristics. Separate patents may cover the underlying TAF molecule or broader prodrug chemistry.
Can a generic avoid US 9,296,769 by using TAF monofumarate?
Potentially, but the alternative must be legally and regulatorily viable. A product using TAF monofumarate would not necessarily satisfy the hemifumarate limitations, but separate patents, bioequivalence requirements, and product-specific FDA standards would remain relevant.
Does claim 6 require every peak in a reference XRPD pattern?
The provided claim language expressly identifies peaks at 6.9 ± 0.2° and 8.6 ± 0.2° 2θ. Whether additional peaks are implicitly required depends on the specification and claim construction. The two listed peaks are the express limitations.
Are the HIV and HBV method claims relevant to a generic drug label?
Yes. A label that instructs use of the product for a claimed HIV or HBV indication can support an induced-infringement theory, although liability depends on the full label, evidence of intent, and the patent's enforceability.
Is a Paragraph IV challenge to this patent enough to launch a generic?
No. A Paragraph IV certification is a legal position, not a court judgment. Launch can remain blocked by litigation, other listed patents, regulatory exclusivity, settlement terms, or commercial risk.
References
-
United States Patent and Trademark Office. (2016). US Patent No. 9,296,769 B2: Tenofovir alafenamide hemifumarate. U.S. Department of Commerce.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2019). Vemlidy prescribing information. Gilead Sciences, Inc.
-
U.S. Food and Drug Administration. (2024). Paragraph IV patent certifications and generic drug approval procedures. U.S. Department of Health and Human Services.
-
United States Code. (2024). 35 U.S.C. §§ 154 and 271; 21 U.S.C. § 355. U.S. Government Publishing Office.
